Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q4 2022 Earnings Call Transcript

Lori Englebert: Yeah. Hi. Thanks for the questions. It’s a good one. So as you mentioned, we have talked about what we’re seeing on Sunosi, so I won’t rehash that. And on Auvelity, we’re still very early. What we’ve done is, we’ve established a platform, the same platform that Sunosi is operating off of. We are very confident in our sales force size as well as the tools that we’ve given them to reach the number of HCPs up that we believe will drive rapid growth. And so it’s a bit too early to really comment on that. But we are very pleased with how the team is using the platform. and how they are helping drive growth that way.

Unidentified Participant: Appreciate that color. Thanks.

Operator: Thank you. I will now turn the call back to Axsome’s CEO for any concluding remarks.

Herriot Tabuteau: Well, thank you again for joining us on the call today. We are proud of the hard work of the Axsome team which is now resulting in meaningful differences in patients’ lives. This is only the development is fine of more great things to come. 2022 was a pivotal year for Axsome. We are not the same for the we were a year ago, and we’re wanting the same company next year with all the strategic growth we anticipate. We are aligned to report value-driving updates with multiple NDA state track candidates and multiple late stage clinical trials in some of the most challenging to treat CNS disorders in the next 12 months to 18 months. Follow is the plan: Axsome has five commercial products in the market by 2025, and we’re hard at work to meet those goals. Thank you. Have a great rest of your day.

Operator: This will conclude today’s conference. Thank you for your participation. You may now disconnect your lines at this time.